On 29 May 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation for rilzabrutinib (Wayrilz), a tablet taken twice daily, to treat adults with immune thrombocytopenia (ITP) when previous treatments have been insufficient. Rilzabrutinib blocks Bruton’s tyrosine kinase, reducing platelet destruction and increasing healthy platelet counts, thereby lowering bleeding risk. The decision followed a phase 3 study of 202 patients, in which 23 % achieved a stable platelet count after 24 weeks, compared with 0 % on placebo. Common side‑effects include diarrhoea, nausea, headache, stomach pain, and joint pain, affecting more than one in ten patients. Patients experiencing side‑effects should consult a healthcare professional and report them via the Yellow Card scheme. The approval was granted to Sanofi B.V and is subject to ongoing safety review.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.